Advertisement

Abstract

Adamantiades-Behçet disease is a multisystem inflammatory disease of unknown etiology, classified as systemic vasculitis involving all types and sizes of blood vessels and characterized clinically by recurrent oral aphthous and genital ulcers, skin lesions, and iridocyclitis/posterior uveitis, occasionally accompanied by arthritis and vascular, gastrointestinal, neurologic, or other manifestations.

References

  1. Aktulga E, Altac M, Muftuoglu A, et al. A double blind study of colchicine in Behcet’s disease. Haematologica. 1980;65:399.PubMedGoogle Scholar
  2. Alpsoy E. Behçet’s disease: treatment of mucocutaneous lesions. Clin Exp Rheumatol. 2005;23:532.PubMedGoogle Scholar
  3. Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behçet’s disease: a randomized placebo-controlled and double-blind study. Arch Dermatol. 2002;138:467.CrossRefGoogle Scholar
  4. Altenburg A, Papoutsis N, Orawa H, et al. Epidemiology and clinical manifestations of Adamantiades-Behçet disease in Germany – Current pathogenetic concepts and therapeutic possibilities. J Dtsch Dermatol Ges. 2006;4:49.CrossRefGoogle Scholar
  5. Altenburg A, Abdel-Naser B, Abdallah M, Seeber H, Zouboulis CC. Practical aspects of management of recurrent aphthous stomatitis. J Eur Acad Dermatol Venereol. 2007;21:1019–26.CrossRefGoogle Scholar
  6. Atmaca LS, Yalçindağ FN, Ozdemir O. Intravitreal triamcinolone acetonide in the management of cystoid macular edema in Behçet’s disease. Graefes Arch Clin Exp Ophthalmol. 2007;245:451.CrossRefGoogle Scholar
  7. Azizlerli G, Koese AK, Sarica R, et al. Prevalence of Behçet’s disease in Istanbul. Turkey Int J Dermatol. 2003;42:803.CrossRefGoogle Scholar
  8. BenEzra D, Cohen E, Chajek T, et al. Evaluation of conventional therapy versus cyclosporine A in Behcet’s syndrome. Transplant Proc. 1988;20 suppl 4:136.PubMedGoogle Scholar
  9. Coskun B, Öztürk P, Saral Y. Are erythema nodosum-like lesions and superficial thrombophlebitis prodromal in terms of visceral involvement in Behçet’s disease? Int J Clin Pract. 2005;59:69.CrossRefGoogle Scholar
  10. Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, et al. Colchicine versus placebo in Behçet’s disease: randomized, double-blind, controlled crossover trial. Mod Rheumatol. 2009;19:542.CrossRefGoogle Scholar
  11. Davies UM, Palmer RG, Denman AM. Treatment with acyclovir does not affect orogenital ulcers in Behcet’s syndrome: a randomized double-blind trial. Br J Rheumatol. 1988;27:300.CrossRefGoogle Scholar
  12. Davies UM, Palmer RG, Denman AM. Treatment with acyclovir does not affect orogenital ulcers in Behcet’s syndrome: a randomized double-blind trial. Br J Rheumatol. 1998;27:300.CrossRefGoogle Scholar
  13. de Menthon M, Lavalley MP, Maldini C, et al. HLA-B51/B5 and the risk of Behçet’s disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum. 2009;61:1287.CrossRefGoogle Scholar
  14. Durrani K, Papaliodis GN. The genetics of Adamantiades-Behcet’s disease. Semin Ophthalmol. 2008;23:73.CrossRefGoogle Scholar
  15. Escudier M, Bagan J, Scully C. Behçet’s disease (Adamantiades syndrome). Oral Dis. 2006;12:78.CrossRefGoogle Scholar
  16. Fietta P. Behçet’s disease: familial clustering and immunogenetics. Clin Exp Rheumatol. 2005;23 suppl 38:S96.PubMedGoogle Scholar
  17. Guillaume-Czitrom S, Berger C, Pajot C, et al. Efficacy and safety of interferon-alpha in the treatment of corticodependent uveitis of paediatric Behcet’s disease. Rheumatology (Oxford). 2007;46:1570.CrossRefGoogle Scholar
  18. Gül A. Behçet’s disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy. 2005;4:81.CrossRefGoogle Scholar
  19. Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128:443.CrossRefGoogle Scholar
  20. Hatemi G, Silman A, Bang D, et al. Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease. Ann Rheum Dis. 2009;68:1528.CrossRefGoogle Scholar
  21. Hirohata S, Kikutchi H. Behçet’s disease. Arthritis Res Ther. 2003;5:139.CrossRefGoogle Scholar
  22. International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet. 1990;335:1078.Google Scholar
  23. International Team for the Revision of the International Criteria for Behçet’s Disease (ITR-ICBD), Davatchi F, Assaad-Khalil S, Calamia KT, Crook JE, Sadeghi-Abdollahi B, Schirmer M, Tzellos T, Zouboulis CC, Akhlagi M, Al-Dalaan A, Alekberova ZS, Ali AA, Altenburg A, Arromdee E, Baltaci M, Bastos M, Benamour S, Ben Ghorbel I, Boyvat A, Carvalho L, Chen W, Ben-Chetrit E, Chams-Davatchi C, Araújo Correia J, Crespo J, Dias C, Dong Y, Paixão-Duarte F, Elmuntaser K, Elonakov AV, Graña Gil J, Haghdoost A-A, Hayani RF, Houman H, Isayeva AR, Jamshidi AR, Kaklamanis P, Kumar A, Kyrgidis A, Madanat W, Nadji A, Namba K, Ohno S, Olivieri I, Vaz Patto J, Pipitone N, de Queiroz MV, Ramos F, Resende C, Rosa CM, Salvarani C, Serra MJ, Shahram F, Shams H, Sharquie KE, Sliti-Khanfir M, Tribolet de Abreu T, Vasconcelos C, Vedes J, Wechsler B, Cheng YK, Zhang Z, Ziaei N. The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28:338–47.CrossRefGoogle Scholar
  24. Jorizzo JL, Abernethy JL, White WL, et al. Mucocutaneous criteria for the diagnosis of Behçet’s disease: an analysis of clinicopathologic data from multiple international centers. J Am Acad Dermatol. 1995;32:968.CrossRefGoogle Scholar
  25. Kaneko F, Oyama T, Sato M et al. Behçet’s disease and diseases for its differential diagnosis in dermatology. An annual report of the Behçet’s Disease Research Committee of Japan, 1999, p 128.Google Scholar
  26. Kiliç H, Zeytin HE, Korkmaz C, et al. Low-dose natural human interferon-alpha lozenges in the treatment of Behçet’s syndrome. Rheumatology (Oxford). 2009;48:1388.CrossRefGoogle Scholar
  27. Krause L. Morbus Adamantiades-Behcet. Ophthalmologe. 2005;102:329.CrossRefGoogle Scholar
  28. Krause L, Altenburg A, Pleyer U, et al. Longterm visual prognosis of patients with ocular Adamantiades-Behçet’s disease treated with interferon-alpha-2a. J Rheumatol. 2008;35:896.PubMedGoogle Scholar
  29. Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet’s disease. Lancet. 1989;1(8647):1093.CrossRefGoogle Scholar
  30. Mat C, Yurdakul S, Uysal S, et al. A double-blind trial of depot corticosteroids in Behçet’s syndrome. Rheumatology (Oxford). 2006;45:348.CrossRefGoogle Scholar
  31. Matsuda T, Ohno S, Hirohata S, et al. Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet’s disease: a randomised, double-blind, placebo-controlled study. Drugs R D. 2003;4:19.CrossRefGoogle Scholar
  32. McCarty MA, Garton RA, Jorizzo JL. Complex aphthosis and Behçet’s disease. Dermatol Clin. 2003;21:41.CrossRefGoogle Scholar
  33. Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behçet’s disease: a double blind, placebo controlled study. J Rheumatol. 2005;32:98.PubMedGoogle Scholar
  34. Moral F, Hamuryudan V, Yurdakul S, et al. Inefficacy of azapropazone in the acute arthritis of Behcet’s syndrome: a randomized, double blind, placebo controlled study. Clin Exp Rheumatol. 1995;13:493.PubMedGoogle Scholar
  35. Nanke Y, Kamatani N, Okamoto T, et al. Irsogladine is effective for recurrent oral ulcers in patients with Behçet’s disease: an open-label, single-centre study. Drugs R D. 2008;9:455.CrossRefGoogle Scholar
  36. Oh SH, Han EC, Lee JH, et al. Comparison of the clinical features of recurrent aphthous stomatitis and Behçet’s disease. Clin Exp Dermatol. 2009;34:e208.CrossRefGoogle Scholar
  37. Ozyazgan Y, Yurdakul S, Yazici H, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet’s syndrome: a single masked trial. Br J Ophthalmol. 1992;76:241.CrossRefGoogle Scholar
  38. Papoutsis N, Bonitsis N, Altenburg A et al. HLA-antigens and their importance as prognostic-marker in Adamantiades-Behçet’s disease (ABD) – is HLA-Bw4 a new prognostic marker? Abstracts of the 14th International Conference on Behçet’s disease, London, UK, 2010, p 163.Google Scholar
  39. Pipitone N, Olivieri I, Cantini F, et al. New approaches in the treatment of Adamantiades-Behçet’s disease. Curr Opin Rheumatol. 2006;18:3.CrossRefGoogle Scholar
  40. Remmers EF, Cosan F, Kirino Y, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet’s disease. Nat Genet. 2010;42:698.CrossRefGoogle Scholar
  41. Sakamoto M, Akazawa K, Nisioka Y, et al. Prognostic factors of vision in patients with Behçet disease. Ophthalmology. 1995;102:317.CrossRefGoogle Scholar
  42. Sfikakis PP, Markomichelakis N, Alpsoy E, et al. Anti-TNF therapy in the management of Behçet’s disease: review and basis for recommendations. Rheumatology (Oxford). 2007;46:736.CrossRefGoogle Scholar
  43. Sharquie KE, Najim RA, Abu-Raghif AR. Dapsone in Behçet’s disease: a double-blind, placebo-controlled, cross-over study. J Dermatol. 2002;29:267.CrossRefGoogle Scholar
  44. Suzuki Kurokawa M, Suzuki N. Behçet’s disease. Clin Exp Med. 2004;4:10.CrossRefGoogle Scholar
  45. Tuncer S, Yilmaz S, Urgancioglu M, et al. Results of intravitreal triamcinolone acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Behçet disease. J Ocul Pharmacol Ther. 2007;23:395.CrossRefGoogle Scholar
  46. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behçet’s disease. N Engl J Med. 1990;322:281.CrossRefGoogle Scholar
  47. Yurdakul S, Mat C, Tuzun Y, et al. A double-blind trial of colchicine in Behçet’s syndrome. Arthritis Rheum. 2001;44:2686.CrossRefGoogle Scholar
  48. Zierhut M, Mizuki N, Ohno S, et al. Immunology and functional genomics of Behçet’s disease. Cell Mol Life Sci. 2003;60:1903.CrossRefGoogle Scholar
  49. Zouboulis CC. Adamantiades-Behçet’s disease. In: Katsambas AD, Lotti TM, editors. European Handbook of Dermatological Treatments. 2nd ed. Berlin Heidelberg: Springer; 2003a. p. 16.CrossRefGoogle Scholar
  50. Zouboulis CC. Morbus Adamantiades-Behçet. In: Mrowietz U, editor. Ciclosporin in der Dermatologie. Stuttgart: Thieme; 2003b. p. 38.Google Scholar
  51. Zouboulis CC, Keitel W. A historical review of early descriptions of Adamantiades-Behçet’s disease. J Invest Dermatol. 2002;119:201.CrossRefGoogle Scholar
  52. Zouboulis CC, May T. Pathogenesis of Adamantiades-Behçet’s disease. Med Microbiol Immunol. 2003;192:149.CrossRefGoogle Scholar
  53. Zouboulis CC, Orfanos CE. Treatment of Adamantiades-Behçet’s disease with systemic interferon alfa. Arch Dermatol. 1998;134:1010.CrossRefGoogle Scholar
  54. Zouboulis CC. Epidemiology of Adamantiades-Behçet’s disease. In: Zierhut M, Ohno S, editors. Immunology of Behçet’s disease. Lisse: Swets & Zeitlinger; 2003c. p. 1.CrossRefGoogle Scholar
  55. Zouboulis CC, Turnbull JR, Martus P. Univariate and multivariate analyses comparing demographic, genetic, clinical, and serological risk factors for severe Adamantiades-Behçet’s disease. Adv Exp Med Biol. 2003a;528:123.CrossRefGoogle Scholar
  56. Zouboulis CC, Kötter I, Djawari D, et al. Current epidemiological data from the German Registry of Adamantiades-Behçet’s disease. Adv Exp Med Biol. 2003b;528:43.CrossRefGoogle Scholar

Further Reading

  1. Bawazeer A, Raffa LH. Clinical experience with adalimumab in the treatment of ocular Behçet disease. Ocul Immunol Inflamm. 2010;18:226.CrossRefGoogle Scholar
  2. Naganuma M, Sakuraba A, Hisamatsu T, et al. Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet’s disease. Inflamm Bowel Dis. 2008;14:1259.CrossRefGoogle Scholar
  3. Niccoli L, Nannini C, Benucci M, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet’s disease: a 24-month follow-up study. Rheumatology (Oxford). 2007;46:1161.CrossRefGoogle Scholar
  4. Pipitone N, Olivieri I, Padula A, et al. Infliximab for the treatment of Neuro-Behçet’s disease: a case series and review of the literature. Arthritis Rheum. 2008;59:285.CrossRefGoogle Scholar
  5. Tognon S, Graziani G, Marcolongo R. Anti-TNF-alpha therapy in seven patients with Behcet’s uveitis: advantages and controversial aspects. Ann N Y Acad Sci. 2007;1110:474.CrossRefGoogle Scholar
  6. Yasui K, Uchida N, Akazawa Y, et al. Thalidomide for treatment of intestinal involvement of juvenile-onset Behçet disease. Inflamm Bowel Dis. 2008;14:396.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Departments of Dermatology, Venereology, Allergology and ImmunologyDessau Medical CenterDessauGermany

Personalised recommendations